Quick Buzz Feed
OncoHost, an AI-driven precision oncology company transforming clinical decision-making through proteomic analysis and machine learning, has been named a winner in the 2026 Artificial Intelligence Excellence Awards, in the health category. The award recognizes organizations applying artificial intelligence in ways that drive real, measurable impact.
The 2026 Artificial Intelligence Excellence Awards honor achievement across a broad range of industries and use cases, spotlighting the companies and leaders moving AI beyond experimentation into practical, accountable deployment. This recognition validates the significant strides made in deploying artificial intelligence to create tangible value and solve complex real-world problems, positioning companies like OncoHost at the forefront of innovation.
OncoHost was recognized for its PROphet® platform, a sophisticated machine learning–based proteomics solution designed to decode systemic host-response biology. This platform accurately predicts immunotherapy outcomes by integrating high-dimensional plasma proteomics with explainable AI. The objective is to deliver clinically actionable insights to newly-diagnosed patients, empowering oncologists to make more precise, data-driven decisions, which in turn reduces patient exposure to ineffective therapies and significantly improves overall treatment outcomes.
"Being recognized in the 2026 Artificial Intelligence Excellence Awards reflects the strength of our strategic vision and the real-world impact of our technology," stated Ofer Sharon, MD, CEO of OncoHost. He emphasized, "We are focused on redefining precision medicine by bringing clinically actionable, explainable AI into everyday oncology practice. By unlocking the biology of the host response, we are improving how treatment decisions are made and are setting a new standard for how AI can be trusted, adopted, and scaled in healthcare." This highlights the company's commitment to innovation and practical application in the medical field.
OncoHost's PROphet® platform represents a significant advancement in oncology AI, moving beyond traditional tumor-centric models to incorporate a comprehensive understanding of the systemic immune response. The platform is built on the analysis of over 7,000 proteins per patient and has been rigorously validated across multiple peer-reviewed studies. This extensive validation demonstrates the platform's strong predictive performance in real-world clinical settings, leading to its adoption across approximately 200 U.S. cancer centers and use by hundreds of oncologists, underscoring its growing and vital role in routine clinical practice.
OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina. The company is dedicated to transforming the approach to precision medicine with the ultimate goal of improving patient outcomes. OncoHost's proprietary platform, PROphet®, is an innovative plasma-based, proteomic pattern analysis tool. This advanced tool utilizes a single blood sample to guide critical immunotherapy decision-making processes. Its first commercial offering, PROphetNSCLC®, is specifically designed to support first-line treatment decisions in metastatic non-small cell lung cancer (NSCLC) by providing clinically actionable insights that extend beyond traditional tumor-only biomarkers, offering a more holistic view for treatment optimization.
Established in 2013, the Artificial Intelligence Excellence Awards annually recognize outstanding organizations, innovative products, dedicated teams, and influential individuals who are effectively leveraging AI technology to solve complex real-world problems. The program comprehensively evaluates advancements across 46 major AI application types and 36 diverse industries, consistently celebrating groundbreaking innovations that contribute to improving the human experience and advancing society as a whole. A distinguished panel of experienced business executives judges the awards, honoring those who are truly committed to utilizing AI as a powerful force for positive change and societal benefit.
Business Intelligence Group (BIG) is an esteemed independent awards organization that has been consistently recognizing outstanding achievement in various business sectors since its inception in 2012. Its comprehensive award programs are rigorously evaluated by a panel of experienced business leaders and practitioners. The core focus of these evaluations is on identifying and celebrating innovations that clearly demonstrate measurable excellence and yield a tangible, real-world impact, thereby highlighting companies and individuals who are making significant contributions to their respective industries.